{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T23:19:27Z","timestamp":1794525567185,"version":"4.9.1"},"reference-count":152,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T00:00:00Z","timestamp":1682380800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.ymgme.2023.107585","type":"journal-article","created":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T20:49:06Z","timestamp":1681764546000},"page":"107585","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"title":["An expert consensus on the recommendations for the use of biomarkers in Fabry disease"],"prefix":"10.1016","volume":"139","author":[{"given":"Alessandro","family":"Burlina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Brand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derralynn","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilkka","family":"Kantola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Kr\u04d3mer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albina","family":"Nowak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"T\u00f8ndel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Wanner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Spada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2023.107585_bb0005","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet J. Rare Dis."},{"issue":"4","key":"10.1016\/j.ymgme.2023.107585_bb0010","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ymgme.2018.02.014","article-title":"Fabry disease revisited: management and treatment recommendations for adult patients","volume":"123","author":"Ortiz","year":"2018","journal-title":"Mol. Genet. Metab."},{"issue":"5","key":"10.1016\/j.ymgme.2023.107585_bb0015","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1681\/ASN.2016090964","article-title":"Characterization of classical and nonclassical Fabry disease: a multicenter study","volume":"28","author":"Arends","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"issue":"1","key":"10.1016\/j.ymgme.2023.107585_bb0020","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/cge.12613","article-title":"X-chromosome inactivation in female patients with Fabry disease","volume":"89","author":"Echevarria","year":"2016","journal-title":"Clin. Genet."},{"key":"10.1016\/j.ymgme.2023.107585_bb0025","unstructured":"Sanofi. Fabrazyme Powder for Concentrate for Solution for Infusion SmPC. Last updated 12 Jul 2021 [Internet]."},{"key":"10.1016\/j.ymgme.2023.107585_bb0030","unstructured":"Amicus Therapeutics UK. Galafold hard capsules SmPC. Last updated 12 Aug 2021. [Internet]."},{"key":"10.1016\/j.ymgme.2023.107585_bb0035","unstructured":"Amicus Therapeutics US. Galafold hard capsules USPI. Last updated Aug 2018 [Internet]."},{"key":"10.1016\/j.ymgme.2023.107585_bb0040","unstructured":"Canadian Agency for Drugs and Technologies in Health. Clinical Review Report: Migalastat (Galafold), https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK533668\/?report=classic."},{"issue":"9","key":"10.1016\/j.ymgme.2023.107585_bb0045","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1681\/ASN.2018030329","article-title":"Effects of enzyme replacement therapy and antidrug antibodies in patients with Fabry disease","volume":"29","author":"Lenders","year":"2018","journal-title":"J. Am. Soc. Nephrol."},{"issue":"Suppl. 2","key":"10.1016\/j.ymgme.2023.107585_bb0050","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/ndt\/gfab038","article-title":"Precision medicine in Fabry disease","volume":"36","author":"Lenders","year":"2021","journal-title":"Nephrol. Dial. Transplant."},{"issue":"6","key":"10.1016\/j.ymgme.2023.107585_bb0055","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s40265-021-01486-1","article-title":"Fabry disease: the current treatment landscape","volume":"81","author":"Lenders","year":"2021","journal-title":"Drugs."},{"issue":"5","key":"10.1016\/j.ymgme.2023.107585_bb0060","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/jmedgenet-2017-104863","article-title":"Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study","volume":"55","author":"Arends","year":"2018","journal-title":"J. Med. Genet."},{"issue":"3","key":"10.1016\/j.ymgme.2023.107585_bb0065","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ymgme.2018.06.004","article-title":"European expert consensus statement on therapeutic goals in Fabry disease","volume":"124","author":"Wanner","year":"2018","journal-title":"Mol. Genet. Metab."},{"issue":"2","key":"10.1016\/j.ymgme.2023.107585_bb0070","doi-asserted-by":"crossref","DOI":"10.3390\/diseases5020015","article-title":"Biomarkers and Imaging findings of Anderson-Fabry disease-what we know now","volume":"5","author":"Beir\u00e3o","year":"2017","journal-title":"Diseases."},{"issue":"21","key":"10.1016\/j.ymgme.2023.107585_bb0075","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21218080","article-title":"Biomarkers in Anderson-Fabry disease","volume":"21","author":"Simonetta","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.ymgme.2023.107585_bb0080","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1067\/mcp.2001.113989","volume":"69","year":"2001","journal-title":"Clin. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.ymgme.2023.107585_bb0085","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s13244-019-0764-0","article-title":"Validated imaging biomarkers as decision-making tools in clinical trials and routine practice: current status and recommendations from the EIBALL* subcommittee of the European Society of Radiology (ESR)","volume":"10","author":"deSouza","year":"2019","journal-title":"Insights Imag."},{"issue":"3","key":"10.1016\/j.ymgme.2023.107585_bb0090","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1177\/1535370217750088","article-title":"Biomarker definitions and their applications","volume":"243","author":"Califf","year":"2018","journal-title":"Exp. Biol. Med. (Maywood)."},{"issue":"8","key":"10.1016\/j.ymgme.2023.107585_bb0095","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0182379","article-title":"Retrospective study of long-term outcomes of enzyme replacement therapy in Fabry disease: analysis of prognostic factors","volume":"12","author":"Arends","year":"2017","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.ymgme.2023.107585_bb0100","article-title":"Pulmonary involvement in Fabry disease: effect of plasma globotriaosylsphingosine and time to initiation of enzyme replacement therapy","volume":"5","author":"Franzen","year":"2018","journal-title":"BMJ Open Respir. Res."},{"issue":"6","key":"10.1016\/j.ymgme.2023.107585_bb0105","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/ki.2010.484","article-title":"Progressive podocyte injury and globotriaosylceramide (GL-3) accumulation in young patients with Fabry disease","volume":"79","author":"Najafian","year":"2011","journal-title":"Kidney Int."},{"issue":"1","key":"10.1016\/j.ymgme.2023.107585_bb0110","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00441-017-2609-9","article-title":"Pathomechanisms of renal Fabry disease","volume":"369","author":"Eikrem","year":"2017","journal-title":"Cell Tissue Res."},{"issue":"1","key":"10.1016\/j.ymgme.2023.107585_bb0115","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ymgme.2019.03.010","article-title":"Low-dose agalsidase beta treatment in male pediatric patients with Fabry disease: A 5-year randomized controlled trial","volume":"127","author":"Ramaswami","year":"2019","journal-title":"Mol. Genet. Metab."},{"issue":"11","key":"10.1016\/j.ymgme.2023.107585_bb0120","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1136\/jmedgenet-2017-104826","article-title":"Reduction of podocyte globotriaosylceramide content in adult male patients with Fabry disease with amenable GLA mutations following 6 months of migalastat treatment","volume":"54","author":"Mauer","year":"2017","journal-title":"J. Med. Genet."},{"issue":"5","key":"10.1016\/j.ymgme.2023.107585_bb0125","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1136\/jmedgenet-2020-106874","article-title":"Treatment switch in Fabry disease- a matter of dose?","volume":"58","author":"Lenders","year":"2020","journal-title":"J. Med. Genet."},{"issue":"1","key":"10.1016\/j.ymgme.2023.107585_bb0130","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1681\/ASN.2014121226","article-title":"Serum-mediated inhibition of enzyme replacement therapy in Fabry Disease","volume":"27","author":"Lenders","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"issue":"2","key":"10.1016\/j.ymgme.2023.107585_bb0135","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ymgme.2017.07.002","article-title":"Genotype, phenotype and disease severity reflected by serum LysoGb3 levels in patients with Fabry disease","volume":"123","author":"Nowak","year":"2018","journal-title":"Mol. Genet. Metab."},{"issue":"12","key":"10.1016\/j.ymgme.2023.107585_bb0140","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1038\/gim.2013.56","article-title":"Changes in plasma and urine globotriaosylceramide levels do not predict Fabry disease progression over 1 year of agalsidase alfa","volume":"15","author":"Schiffmann","year":"2013","journal-title":"Genet. Med."},{"issue":"4","key":"10.1016\/j.ymgme.2023.107585_bb0145","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1681\/ASN.2013121322","article-title":"Fabry disease: dose matters","volume":"25","author":"Warnock","year":"2014","journal-title":"J. Am. Soc. Nephrol."},{"issue":"1","key":"10.1016\/j.ymgme.2023.107585_bb0150","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41436-020-00968-z","article-title":"Assessment of plasma lyso-Gb(3) for clinical monitoring of treatment response in migalastat-treated patients with Fabry disease","volume":"23","author":"Bichet","year":"2021","journal-title":"Genet. Med."},{"issue":"10","key":"10.1016\/j.ymgme.2023.107585_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmg.2019.103702","article-title":"Why systematic literature reviews in Fabry disease should include all published evidence","volume":"62","author":"Elliott","year":"2019","journal-title":"Eur. J. Med. Genet."},{"key":"10.1016\/j.ymgme.2023.107585_bb0160","article-title":"The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: a systematic literature review by a European panel of experts","volume":"19","author":"Germain","year":"2019","journal-title":"Mol. Genet. Metab. Rep."},{"issue":"3","key":"10.1016\/j.ymgme.2023.107585_bb0165","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ymgme.2018.04.007","article-title":"The effect of enzyme replacement therapy on clinical outcomes in paediatric patients with Fabry disease - A systematic literature review by a European panel of experts","volume":"126","author":"Spada","year":"2019","journal-title":"Mol. Genet. Metab."},{"issue":"3","key":"10.1016\/j.ymgme.2023.107585_bb0170","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ymgme.2018.09.007","article-title":"The effect of enzyme replacement therapy on clinical outcomes in female patients with Fabry disease - A systematic literature review by a European panel of experts","volume":"126","author":"Germain","year":"2019","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2023.107585_bb0175","unstructured":"CEBM, Oxford Centre for Evidence-Based Medicine \u2013 Levels of Evidence. Available from: http:\/\/www.cebm.net\/oxford-centre-evidence-based-medicine-levels-evidence-march-2009."},{"issue":"1","key":"10.1016\/j.ymgme.2023.107585_bb0180","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ymgme.2010.11.155","article-title":"Expert opinion on temporary treatment recommendations for Fabry disease during the shortage of enzyme replacement therapy (ERT)","volume":"102","author":"Linthorst","year":"2011","journal-title":"Mol. Genet. Metab."},{"issue":"12","key":"10.1016\/j.ymgme.2023.107585_bb0185","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1515\/cclm-2018-1301","article-title":"Plasma and dried blood spot lysosphingolipids for the diagnosis of different sphingolipidoses: a comparative study","volume":"57","author":"Polo","year":"2019","journal-title":"Clin. Chem. Lab. Med."},{"issue":"4","key":"10.1016\/j.ymgme.2023.107585_bb0190","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.ymgme.2017.06.006","article-title":"Correlation of Lyso-Gb3 levels in dried blood spots and sera from patients with classic and Later-Onset Fabry disease","volume":"121","author":"Nowak","year":"2017","journal-title":"Mol. Genet. Metab."},{"issue":"5","key":"10.1016\/j.ymgme.2023.107585_bb0195","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1002\/cpt.1321","article-title":"Oral chaperone therapy migalastat for treating Fabry disease: enzymatic response and serum biomarker changes after 1 year","volume":"105","author":"M\u00fcntze","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"issue":"4","key":"10.1016\/j.ymgme.2023.107585_bb0200","doi-asserted-by":"crossref","first-page":"569","DOI":"10.2215\/CJN.09480819","article-title":"The changing landscape of Fabry disease","volume":"15","author":"Svarstad","year":"2020","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"1","key":"10.1016\/j.ymgme.2023.107585_bb0205","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/gim.2018.31","article-title":"Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis","volume":"21","author":"Maruyama","year":"2019","journal-title":"Genet. Med."},{"issue":"2","key":"10.1016\/j.ymgme.2023.107585_bb0210","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s10545-017-0098-3","article-title":"Newborn screening for lysosomal storage disorders by tandem mass spectrometry in North East Italy","volume":"41","author":"Burlina","year":"2018","journal-title":"J. Inherit. Metab. Dis."},{"issue":"7","key":"10.1016\/j.ymgme.2023.107585_bb0215","doi-asserted-by":"crossref","first-page":"951","DOI":"10.3390\/biom11070951","article-title":"Newborn screening for Fabry disease in Northeastern Italy: results of five years of experience","volume":"11","author":"Gragnaniello","year":"2021","journal-title":"Biomolecules."},{"issue":"6","key":"10.1016\/j.ymgme.2023.107585_bb0220","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/1873-3468.12104","article-title":"Lysosomal glycosphingolipid catabolism by acid ceramidase: formation of glycosphingoid bases during deficiency of glycosidases","volume":"590","author":"Ferraz","year":"2016","journal-title":"FEBS Lett."},{"issue":"1","key":"10.1016\/j.ymgme.2023.107585_bb0225","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.bbadis.2010.09.007","article-title":"Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy","volume":"1812","author":"van Breemen","year":"2011","journal-title":"Biochim. Biophys. Acta"},{"issue":"7","key":"10.1016\/j.ymgme.2023.107585_bb0230","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1136\/jmedgenet-2015-103486","article-title":"Time to treatment benefit for adult patients with Fabry disease receiving agalsidase \u03b2: data from the Fabry Registry","volume":"53","author":"Ortiz","year":"2016","journal-title":"J. Med. Genet."},{"issue":"3","key":"10.1016\/j.ymgme.2023.107585_bb0235","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ymgme.2010.03.020","article-title":"Plasma globotriaosylsphingosine as a biomarker of Fabry disease","volume":"100","author":"Togawa","year":"2010","journal-title":"Mol. Genet. Metab."},{"issue":"9","key":"10.1016\/j.ymgme.2023.107585_bb0240","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.bbadis.2010.05.003","article-title":"Plasma globotriaosylsphingosine: diagnostic value and relation to clinical manifestations of Fabry disease","volume":"1802","author":"Rombach","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"issue":"2","key":"10.1016\/j.ymgme.2023.107585_bb0245","doi-asserted-by":"crossref","first-page":"360","DOI":"10.2215\/CJN.06090809","article-title":"Biomarkers of Fabry disease nephropathy","volume":"5","author":"Schiffmann","year":"2010","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"8","key":"10.1016\/j.ymgme.2023.107585_bb0250","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","article-title":"Elevated globotriaosylsphingosine is a hallmark of Fabry disease","volume":"105","author":"Aerts","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"8","key":"10.1016\/j.ymgme.2023.107585_bb0255","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1093\/ndt\/gfx319","article-title":"Fabry disease under enzyme replacement therapy-new insights in efficacy of different dosages","volume":"33","author":"Kr\u00e4mer","year":"2018","journal-title":"Nephrol. Dial. Transplant."},{"issue":"2","key":"10.1016\/j.ymgme.2023.107585_bb0260","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/jimd.12167","article-title":"Fabry disease genotype, phenotype, and migalastat amenability: Insights from a national cohort","volume":"43","author":"Nowak","year":"2020","journal-title":"J. Inherit. Metab. Dis."},{"issue":"3","key":"10.1016\/j.ymgme.2023.107585_bb0265","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1093\/ehjcvp\/pvab025","article-title":"Treatment of Fabry disease with migalastat\u2014outcome from a prospective 24 months observational multicenter study (FAMOUS)","volume":"8","author":"Lenders","year":"2022","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"issue":"5","key":"10.1016\/j.ymgme.2023.107585_bb0270","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.33594\/000000077","article-title":"Enzyme replacement therapy clears Gb3 deposits from a podocyte cell culture model of fabry disease but fails to restore altered cellular signaling","volume":"52","author":"Braun","year":"2019","journal-title":"Cell. Physiol. Biochem."},{"issue":"2","key":"10.1016\/j.ymgme.2023.107585_bb0275","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ymgme.2019.12.010","article-title":"FAbry STabilization indEX (FASTEX): clinical evaluation of disease progression in Fabry patients","volume":"129","author":"Lenders","year":"2020","journal-title":"Mol. Genet. Metab."},{"issue":"4","key":"10.1016\/j.ymgme.2023.107585_bb0280","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0193550","article-title":"Phenotype and biochemical heterogeneity in late onset Fabry disease defined by N215S mutation","volume":"13","author":"Lavalle","year":"2018","journal-title":"PLoS One"},{"issue":"13","key":"10.1016\/j.ymgme.2023.107585_bb0285","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1136\/jmedgenet-2020-107338","article-title":"Lyso-Gb3 associates with adverse long-term outcome in patients with Fabry disease","volume":"59","author":"Nowak","year":"2022","journal-title":"J. Med. Genet."},{"issue":"1-2","key":"10.1016\/j.ymgme.2023.107585_bb0290","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ymgme.2017.08.004","article-title":"A simple method for quantification of plasma globotriaosylsphingosine: utility for Fabry disease","volume":"122","author":"Talbot","year":"2017","journal-title":"Mol. Genet. Metab."},{"issue":"2","key":"10.1016\/j.ymgme.2023.107585_bb0295","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ymgme.2017.10.001","article-title":"The utility of the FIPI score in predicting long-term clinical outcomes in patients with Fabry disease receiving enzyme replacement therapy with agalsidase alfa","volume":"123","author":"Mac Lochlainn","year":"2018","journal-title":"Mol. Genet. Metab."},{"issue":"3","key":"10.1016\/j.ymgme.2023.107585_bb0300","first-page":"1683","article-title":"Altered immune phenotypes in subjects with Fabry disease and responses to switching from agalsidase alfa to agalsidase beta","volume":"11","author":"Limgala","year":"2019","journal-title":"Am. J. Transl. Res."},{"issue":"7 Pt 1","key":"10.1016\/j.ymgme.2023.107585_bb0305","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/j.jcmg.2018.11.039","article-title":"The role of cardiac imaging in the diagnosis and management of Anderson-Fabry disease","volume":"12","author":"Perry","year":"2019","journal-title":"JACC Cardiovasc. Imaging"},{"issue":"4","key":"10.1016\/j.ymgme.2023.107585_bb0310","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1136\/jmedgenet-2017-105080","article-title":"Fabry Disease: prevalence of affected males and heterozygotes with pathogenic GLA mutations identified by screening renal, cardiac and stroke clinics, 1995-2017","volume":"55","author":"Doheny","year":"2018","journal-title":"J. Med. Genet."},{"issue":"4","key":"10.1016\/j.ymgme.2023.107585_bb0315","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/mgg3.389","article-title":"Phenotypic characteristics of the p.Asn215Ser (p.N215S) GLA mutation in male and female patients with Fabry disease: a multicenter Fabry Registry study","volume":"6","author":"Germain","year":"2018","journal-title":"Mol. Genet. Genom. Med."},{"issue":"2","key":"10.1016\/j.ymgme.2023.107585_bb0320","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ymgme.2019.07.012","article-title":"Founder effect of Fabry disease due to p.F113L mutation: clinical profile of a late-onset phenotype","volume":"129","author":"Azevedo","year":"2020","journal-title":"Mol. Genet. Metab."},{"issue":"23","key":"10.1016\/j.ymgme.2023.107585_bb0325","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1016\/j.jacc.2016.09.943","article-title":"Later onset Fabry disease, cardiac damage progress in silence: experience with a highly prevalent mutation","volume":"68","author":"Hsu","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"issue":"7","key":"10.1016\/j.ymgme.2023.107585_bb0330","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1002\/ejhf.1960","article-title":"An expert consensus document on the management of cardiovascular manifestations of Fabry disease","volume":"22","author":"Linhart","year":"2020","journal-title":"Eur. J. Heart Fail."},{"issue":"4","key":"10.1016\/j.ymgme.2023.107585_bb0335","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1161\/CIRCULATIONAHA.108.794529","article-title":"Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment","volume":"119","author":"Weidemann","year":"2009","journal-title":"Circulation."},{"issue":"12","key":"10.1016\/j.ymgme.2023.107585_bb0340","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1136\/heartjnl-2014-306782","article-title":"Clinical and genetic predictors of major cardiac events in patients with Anderson-Fabry Disease","volume":"101","author":"Patel","year":"2015","journal-title":"Heart."},{"issue":"4","key":"10.1016\/j.ymgme.2023.107585_bb0345","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/joim.12077","article-title":"Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications","volume":"274","author":"Weidemann","year":"2013","journal-title":"J. Intern. Med."},{"issue":"1","key":"10.1016\/j.ymgme.2023.107585_bb0350","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12947-019-0151-5","article-title":"Role of cardiac imaging in Anderson-Fabry cardiomyopathy","volume":"17","author":"Serra","year":"2019","journal-title":"Cardiovasc. Ultrasound"},{"issue":"7","key":"10.1016\/j.ymgme.2023.107585_bb0355","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1093\/ehjci\/jeaa101","article-title":"The myocardial phenotype of Fabry disease pre-hypertrophy and pre-detectable storage","volume":"22","author":"Augusto","year":"2021","journal-title":"Eur. Heart J. Cardiovasc. Imaging"},{"key":"10.1016\/j.ymgme.2023.107585_bb0360","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3389\/fcvm.2016.00007","article-title":"Electrocardiographic changes and arrhythmia in Fabry disease","volume":"3","author":"Namdar","year":"2016","journal-title":"Front. Cardiovasc. Med."},{"issue":"6","key":"10.1016\/j.ymgme.2023.107585_bb0365","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.117.007168","article-title":"Cardiac phenotype of prehypertrophic Fabry disease","volume":"11","author":"Nordin","year":"2018","journal-title":"Circ. Cardiovasc. Imag."},{"issue":"4","key":"10.1016\/j.ymgme.2023.107585_bb0370","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.118.008424","article-title":"Predictors of clinical evolution in prehypertrophic Fabry disease","volume":"12","author":"Camporeale","year":"2019","journal-title":"Circ. Cardiovasc. Imag."},{"issue":"3","key":"10.1016\/j.ymgme.2023.107585_bb0375","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.119.010171","article-title":"Myocardial edema, myocyte injury, and disease severity in Fabry disease","volume":"13","author":"Augusto","year":"2020","journal-title":"Circ. Cardiovasc. Imag."},{"issue":"2","key":"10.1016\/j.ymgme.2023.107585_bb0380","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ymgme.2018.11.005","article-title":"Early detection of organ involvement in Fabry disease by biomarker assessment in conjunction with LGE cardiac MRI: results from the SOPHIA study","volume":"126","author":"Weidemann","year":"2019","journal-title":"Mol. Genet. Metab."},{"issue":"7","key":"10.1016\/j.ymgme.2023.107585_bb0385","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.jacc.2020.12.024","article-title":"Cardiac involvement in Fabry disease: JACC review topic of the week","volume":"77","author":"Pieroni","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"issue":"3","key":"10.1016\/j.ymgme.2023.107585_bb0390","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ymgme.2017.09.004","article-title":"Contribution of inflammatory pathways to Fabry disease pathogenesis","volume":"122","author":"Rozenfeld","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2023.107585_bb0395","first-page":"1","article-title":"Innate and adaptive immune response in Fabry disease","volume":"22","author":"Mauhin","year":"2015","journal-title":"JIMD Rep."},{"issue":"21","key":"10.1016\/j.ymgme.2023.107585_bb0400","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.009098","article-title":"Elevated inflammatory plasma biomarkers in patients with Fabry disease: a critical link to heart failure with preserved ejection fraction","volume":"7","author":"Yogasundaram","year":"2018","journal-title":"J. Am. Heart Assoc."},{"issue":"8 Pt 2","key":"10.1016\/j.ymgme.2023.107585_bb0405","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/j.jcmg.2018.03.020","article-title":"Proposed stages of myocardial phenotype development in Fabry disease","volume":"12","author":"Nordin","year":"2019","journal-title":"JACC Cardiovasc. Imaging"},{"issue":"12","key":"10.1016\/j.ymgme.2023.107585_bb0410","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.119.009430","article-title":"Myocardial storage, inflammation, and cardiac phenotype in Fabry disease after one year of enzyme replacement therapy","volume":"12","author":"Nordin","year":"2019","journal-title":"Circ. Cardiovasc. Imag."},{"issue":"1","key":"10.1016\/j.ymgme.2023.107585_bb0415","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.amjcard.2012.08.055","article-title":"Role of serum N-terminal pro-brain natriuretic peptide measurement in diagnosis of cardiac involvement in patients with anderson-fabry disease","volume":"111","author":"Coats","year":"2013","journal-title":"Am. J. Cardiol."},{"issue":"11","key":"10.1016\/j.ymgme.2023.107585_bb0420","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0140627","article-title":"Left ventricular geometry and blood pressure as predictors of adverse progression of Fabry cardiomyopathy","volume":"10","author":"Kr\u00e4mer","year":"2015","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.ymgme.2023.107585_bb0425","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0091757","article-title":"Continuous cardiac troponin I release in Fabry disease","volume":"9","author":"Feustel","year":"2014","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.ymgme.2023.107585_bb0430","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2018-000803","article-title":"Association and diagnostic utility of diastolic dysfunction and myocardial fibrosis in patients with Fabry disease","volume":"5","author":"Liu","year":"2018","journal-title":"Open Heart."},{"issue":"6","key":"10.1016\/j.ymgme.2023.107585_bb0435","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.002839","article-title":"High-sensitivity troponin: a clinical blood biomarker for staging cardiomyopathy in Fabry disease","volume":"5","author":"Seydelmann","year":"2016","journal-title":"J. Am. Heart Assoc."},{"issue":"1","key":"10.1016\/j.ymgme.2023.107585_bb0440","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s40360-017-0152-7","article-title":"Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-na\u00efve Fabry disease patients","volume":"18","author":"Tsuboi","year":"2017","journal-title":"BMC Pharmacol. Toxicol."},{"issue":"1","key":"10.1016\/j.ymgme.2023.107585_bb0445","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13052-016-0320-1","article-title":"Metabolic progression to clinical phenotype in classic Fabry disease","volume":"43","author":"Spada","year":"2017","journal-title":"Ital. J. Pediatr."},{"issue":"6","key":"10.1016\/j.ymgme.2023.107585_bb0450","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.amjcard.2013.04.060","article-title":"Usefulness of high-sensitivity cardiac troponin T and brain natriuretic peptide as biomarkers of myocardial fibrosis in patients with hypertrophic cardiomyopathy","volume":"112","author":"Kawasaki","year":"2013","journal-title":"Am. J. Cardiol."},{"issue":"1","key":"10.1016\/j.ymgme.2023.107585_bb0455","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1161\/01.CIR.88.1.101","article-title":"Cardiac troponin I. A marker with high specificity for cardiac injury","volume":"88","author":"Adams","year":"1993","journal-title":"Circulation."},{"issue":"12","key":"10.1016\/j.ymgme.2023.107585_bb0460","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1253\/circj.CJ-18-0378","article-title":"Correlations between serum cholesterol and vascular lesions in Fabry disease patients","volume":"82","author":"Katsuta","year":"2018","journal-title":"Circ. J."},{"issue":"2","key":"10.1016\/j.ymgme.2023.107585_bb0465","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2215\/CJN.06900909","article-title":"Enzyme replacement therapy and Fabry nephropathy","volume":"5","author":"Warnock","year":"2010","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"4","key":"10.1016\/j.ymgme.2023.107585_bb0470","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1159\/000502907","article-title":"Early biomarkers of Fabry nephropathy: a review of the literature","volume":"143","author":"Riccio","year":"2019","journal-title":"Nephron."},{"issue":"5","key":"10.1016\/j.ymgme.2023.107585_bb0475","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s00467-012-2222-9","article-title":"Renal complications of Fabry disease in children","volume":"28","author":"Najafian","year":"2013","journal-title":"Pediatr. Nephrol."},{"key":"10.1016\/j.ymgme.2023.107585_bb0480","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.2147\/DDDT.S249433","article-title":"Analysis of renal and cardiac outcomes in male participants in the Fabry outcome survey starting Agalsidase Alfa enzyme replacement therapy before and after 18 years of age","volume":"14","author":"Parini","year":"2020","journal-title":"Drug Des. Devel. Ther."},{"issue":"9","key":"10.1016\/j.ymgme.2023.107585_bb0485","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.2215\/CJN.01820217","article-title":"Long-term dose-dependent agalsidase effects on kidney histology in Fabry disease","volume":"12","author":"Skrunes","year":"2017","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"4","key":"10.1016\/j.ymgme.2023.107585_bb0490","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1136\/jmedgenet-2016-104178","article-title":"Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study","volume":"54","author":"Hughes","year":"2017","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgme.2023.107585_bb0495","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.cca.2017.12.033","article-title":"Investigation of correlation of urinary globotriaosylceramide (Gb3) levels with markers of renal function in patients with Fabry disease","volume":"478","author":"Moura","year":"2018","journal-title":"Clin. Chim. Acta"},{"issue":"9","key":"10.1016\/j.ymgme.2023.107585_bb0500","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1038\/s41436-019-0451-z","article-title":"Efficacy of the pharmacologic chaperone migalastat in a subset of male patients with the classic phenotype of Fabry disease and migalastat-amenable variants: data from the phase 3 randomized, multicenter, double-blind clinical trial and extension study","volume":"21","author":"Germain","year":"2019","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2023.107585_bb0505","doi-asserted-by":"crossref","first-page":"1287289","DOI":"10.1155\/2017\/1287289","article-title":"Expression of uPAR in urinary podocytes of patients with Fabry disease","volume":"2017","author":"Trimarchi","year":"2017","journal-title":"Int. J. Nephrol."},{"key":"10.1016\/j.ymgme.2023.107585_bb0510","first-page":"4027606","article-title":"Variables associated with a urinary MicroRNAs excretion profile indicative of renal fibrosis in Fabry disease patients","volume":"2019","author":"Jaurretche","year":"2019","journal-title":"Int. J. Chron. Dis."},{"issue":"9","key":"10.1016\/j.ymgme.2023.107585_bb0515","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1093\/ndt\/gfy357","article-title":"Age-related renal function decline in Fabry disease patients on enzyme replacement therapy: a longitudinal cohort study","volume":"34","author":"Madsen","year":"2019","journal-title":"Nephrol. Dial. Transplant."},{"issue":"12","key":"10.1016\/j.ymgme.2023.107585_bb0520","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0168346","article-title":"Urinary podocyte loss is increased in patients with Fabry disease and correlates with clinical severity of fabry nephropathy","volume":"11","author":"Fall","year":"2016","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.ymgme.2023.107585_bb0525","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1159\/000369309","article-title":"Foot process effacement is an early marker of nephropathy in young classic Fabry patients without albuminuria","volume":"129","author":"T\u00f8ndel","year":"2015","journal-title":"Nephron."},{"issue":"3","key":"10.1016\/j.ymgme.2023.107585_bb0530","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1093\/ndt\/gfr420","article-title":"Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation","volume":"27","author":"Warnock","year":"2012","journal-title":"Nephrol. Dial. Transplant."},{"issue":"5","key":"10.1016\/j.ymgme.2023.107585_bb0535","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0124987","article-title":"Characterization of early disease status in treatment-naive male paediatric patients with Fabry disease enrolled in a randomized clinical trial","volume":"10","author":"Wijburg","year":"2015","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.ymgme.2023.107585_bb0540","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1093\/ndt\/gfp031","article-title":"Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy","volume":"24","author":"Schiffmann","year":"2009","journal-title":"Nephrol. Dial. Transplant."},{"issue":"1","key":"10.1016\/j.ymgme.2023.107585_bb0545","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/ckj\/sfy081","article-title":"Podocyturia: why it may have added value in rare diseases","volume":"12","author":"Sanchez-Ni\u00f1o","year":"2019","journal-title":"Clin. Kidney J."},{"issue":"9","key":"10.1016\/j.ymgme.2023.107585_bb0550","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.3390\/genes11091091","article-title":"Biomarkers of Fabry nephropathy: review and future perspective","volume":"11","author":"Levstek","year":"2020","journal-title":"Genes (Basel)"},{"issue":"4","key":"10.1016\/j.ymgme.2023.107585_bb0555","first-page":"437","article-title":"Cystatin C as a marker of early changes of renal function in Fabry nephropathy","volume":"20","author":"Feriozzi","year":"2007","journal-title":"J. Nephrol."},{"issue":"3","key":"10.1016\/j.ymgme.2023.107585_bb0560","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ymgme.2011.06.021","article-title":"Cystatin C and NT-proBNP as prognostic biomarkers in Fabry disease","volume":"104","author":"Torralba-Cabeza","year":"2011","journal-title":"Mol. Genet. Metab."},{"issue":"2","key":"10.1016\/j.ymgme.2023.107585_bb0565","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ymgme.2018.11.008","article-title":"Antibodies against recombinant alpha-galactosidase A in Fabry disease: subclass analysis and impact on response to treatment","volume":"126","author":"van der Veen","year":"2019","journal-title":"Mol. Genet. Metab."},{"issue":"12","key":"10.1016\/j.ymgme.2023.107585_bb0570","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1681\/ASN.2018070740","article-title":"Dose-dependent effect of enzyme replacement therapy on neutralizing antidrug antibody titers and clinical outcome in patients with Fabry disease","volume":"29","author":"Lenders","year":"2018","journal-title":"J. Am. Soc. Nephrol."},{"issue":"4","key":"10.1016\/j.ymgme.2023.107585_bb0575","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.ymgme.2019.02.005","article-title":"Safety and effectiveness of enzyme replacement therapy with agalsidase alfa in patients with Fabry disease: Post-marketing surveillance in Japan","volume":"126","author":"Sasa","year":"2019","journal-title":"Mol. Genet. Metab."},{"issue":"3","key":"10.1016\/j.ymgme.2023.107585_bb0580","first-page":"173","article-title":"Switch from agalsidase beta to agalsidase alfa in the enzyme replacement therapy of patients with Fabry disease in Latin America","volume":"77","author":"Ripeau","year":"2017","journal-title":"Medicina (B Aires)."},{"key":"10.1016\/j.ymgme.2023.107585_bb0585","article-title":"Long-term follow-up of renal function in patients treated with migalastat for Fabry disease","volume":"28","author":"Bichet","year":"2021","journal-title":"Mol. Genet. Metab. Rep."},{"issue":"5","key":"10.1016\/j.ymgme.2023.107585_bb0590","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1053\/j.ajkd.2007.12.032","article-title":"Renal biopsy findings in children and adolescents with Fabry disease and minimal albuminuria","volume":"51","author":"T\u00f8ndel","year":"2008","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.ymgme.2023.107585_bb0595","article-title":"Copious podocyturia without proteinuria and with normal renal function in a young adult with Fabry disease","volume":"2015","author":"Trimarchi","year":"2015","journal-title":"Case Rep. Nephrol."},{"issue":"4","key":"10.1016\/j.ymgme.2023.107585_bb0600","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1681\/ASN.2019050497","article-title":"Accumulation of globotriaosylceramide in podocytes in Fabry nephropathy is associated with progressive podocyte loss","volume":"31","author":"Najafian","year":"2020","journal-title":"J. Am. Soc. Nephrol."},{"issue":"2","key":"10.1016\/j.ymgme.2023.107585_bb0605","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.beem.2015.01.006","article-title":"The role of antibodies in enzyme treatments and therapeutic strategies","volume":"29","author":"Bigger","year":"2015","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"issue":"5","key":"10.1016\/j.ymgme.2023.107585_bb0610","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/j.xphs.2018.12.014","article-title":"Immunogenicity of protein pharmaceuticals","volume":"108","author":"Dingman","year":"2019","journal-title":"J. Pharm. Sci."},{"issue":"17","key":"10.1016\/j.ymgme.2023.107585_bb0615","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1007\/s40265-021-01621-y","article-title":"Mechanisms of neutralizing anti-drug antibody formation and clinical relevance on therapeutic efficacy of enzyme replacement therapies in Fabry disease","volume":"81","author":"Lenders","year":"2021","journal-title":"Drugs."},{"issue":"3","key":"10.1016\/j.ymgme.2023.107585_bb0620","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ymgme.2011.12.006","article-title":"Anti-\u03b1-galactosidase A antibody response to agalsidase beta treatment: data from the Fabry Registry","volume":"105","author":"Wilcox","year":"2012","journal-title":"Mol. Genet. Metab."},{"issue":"5","key":"10.1016\/j.ymgme.2023.107585_bb0625","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/j.1365-2125.2009.03501.x","article-title":"Enzyme therapy in Fabry disease: severe adverse events associated with anti-agalsidase cross-reactive IgG antibodies","volume":"68","author":"Tesmoingt","year":"2009","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ymgme.2023.107585_bb0630","first-page":"109","article-title":"Severe infusion reactions to fabry enzyme replacement therapy: rechallenge after tracheostomy","volume":"5","author":"Nicholls","year":"2012","journal-title":"JIMD Rep."},{"issue":"21","key":"10.1016\/j.ymgme.2023.107585_bb0635","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease: a randomized controlled trial","volume":"285","author":"Schiffmann","year":"2001","journal-title":"JAMA."},{"issue":"16","key":"10.1016\/j.ymgme.2023.107585_bb0640","doi-asserted-by":"crossref","first-page":"5784","DOI":"10.3390\/ijms21165784","article-title":"Predicting the development of anti-drug antibodies against recombinant alpha-galactosidase A in male patients with classical fabry disease","volume":"21","author":"van der Veen","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.ymgme.2023.107585_bb0645","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/jimd.12176","article-title":"Neutralising anti-drug antibodies in Fabry disease can inhibit endothelial enzyme uptake and activity","volume":"43","author":"Stappers","year":"2020","journal-title":"J. Inherit. Metab. Dis."},{"issue":"3","key":"10.1016\/j.ymgme.2023.107585_bb0650","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/jimd.12080","article-title":"Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: A 1-year Phase 1\/2 clinical trial","volume":"42","author":"Schiffmann","year":"2019","journal-title":"J. Inherit. Metab. Dis."},{"issue":"1","key":"10.1016\/j.ymgme.2023.107585_bb0655","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s13023-018-0877-4","article-title":"Deep characterization of the anti-drug antibodies developed in Fabry disease patients, a prospective analysis from the French multicenter cohort FFABRY","volume":"13","author":"Mauhin","year":"2018","journal-title":"Orphanet. J. Rare Dis."},{"issue":"4","key":"10.1016\/j.ymgme.2023.107585_bb0660","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s10157-017-1525-3","article-title":"Plasma lyso-Gb3: a biomarker for monitoring fabry patients during enzyme replacement therapy","volume":"22","author":"Sakuraba","year":"2018","journal-title":"Clin. Exp. Nephrol."},{"issue":"11","key":"10.1016\/j.ymgme.2023.107585_bb0665","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1136\/jmedgenet-2017-104704","article-title":"Fabry disease: characterisation of the plasma proteome pre- and post-enzyme replacement therapy","volume":"54","author":"Heo","year":"2017","journal-title":"J. Med. Genet."},{"issue":"3","key":"10.1016\/j.ymgme.2023.107585_bb0670","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/joim.12647","article-title":"Impact of immunosuppressive therapy on therapy-neutralizing antibodies in transplanted patients with Fabry disease","volume":"282","author":"Lenders","year":"2017","journal-title":"J. Intern. Med."},{"issue":"10","key":"10.1016\/j.ymgme.2023.107585_bb0675","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0047805","article-title":"Long-term effect of antibodies against infused alpha-galactosidase A in Fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcome","volume":"7","author":"Rombach","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgme.2023.107585_bb0680","first-page":"95","article-title":"Reduction of plasma globotriaosylsphingosine levels after switching from agalsidase alfa to agalsidase beta as enzyme replacement therapy for Fabry disease","volume":"25","author":"Goker-Alpan","year":"2016","journal-title":"JIMD Rep."},{"key":"10.1016\/j.ymgme.2023.107585_bb0685","first-page":"4","article-title":"The central nervous system involvement in Fabry disease: a review","author":"Burlina","year":"2016","journal-title":"J. Inborn Errors Metabol. Screen."},{"issue":"6","key":"10.1016\/j.ymgme.2023.107585_bb0690","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1007\/s13244-018-0664-8","article-title":"Neuroimaging in Fabry disease: current knowledge and future directions","volume":"9","author":"Cocozza","year":"2018","journal-title":"Insights Imag."},{"issue":"2","key":"10.1016\/j.ymgme.2023.107585_bb0695","doi-asserted-by":"crossref","first-page":"497","DOI":"10.3390\/neurolint14020041","article-title":"Pulvinar sign, stroke and their relationship with Fabry disease: a systematic review and metanalysis","volume":"14","author":"Ort\u00edz","year":"2022","journal-title":"Neurol. Int."},{"issue":"3","key":"10.1016\/j.ymgme.2023.107585_bb0700","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1007\/s00415-020-10209-7","article-title":"MRI-visible perivascular spaces as an imaging biomarker in Fabry disease","volume":"268","author":"Lyndon","year":"2021","journal-title":"J. Neurol."},{"issue":"1","key":"10.1016\/j.ymgme.2023.107585_bb0705","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1161\/STROKEAHA.114.006283","article-title":"Cerebrovascular involvement in Fabry disease: current status of knowledge","volume":"46","author":"Kolodny","year":"2015","journal-title":"Stroke."},{"issue":"6","key":"10.1016\/j.ymgme.2023.107585_bb0710","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/j.jstrokecerebrovasdis.2016.02.019","article-title":"Characteristics of cerebral microbleeds in patients with Fabry disease","volume":"25","author":"Kono","year":"2016","journal-title":"J. Stroke Cerebrovasc. Dis."},{"issue":"2","key":"10.1016\/j.ymgme.2023.107585_bb0715","doi-asserted-by":"crossref","first-page":"136","DOI":"10.2174\/1567202611666140310102248","article-title":"Basal ganglia enlarged perivascular spaces are linked to cognitive function in patients with cerebral small vessel disease","volume":"11","author":"Huijts","year":"2014","journal-title":"Curr. Neurovasc. Res."},{"issue":"2","key":"10.1016\/j.ymgme.2023.107585_bb0720","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s10545-013-9643-x","article-title":"Cognitive dysfunction and depression in Fabry disease: a systematic review","volume":"37","author":"Bolsover","year":"2014","journal-title":"J. Inherit. Metab. Dis."},{"issue":"1","key":"10.1016\/j.ymgme.2023.107585_bb0725","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3174\/ajnr.A2832","article-title":"Brain and spinal MR imaging findings in mucopolysaccharidoses: a review","volume":"34","author":"Zafeiriou","year":"2013","journal-title":"AJNR Am. J. Neuroradiol."},{"issue":"4","key":"10.1016\/j.ymgme.2023.107585_bb0730","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s00330-008-1202-8","article-title":"Potential surrogate markers of cerebral microvascular angiopathy in asymptomatic subjects at risk of stroke","volume":"19","author":"Selvarajah","year":"2009","journal-title":"Eur. Radiol."},{"issue":"3","key":"10.1016\/j.ymgme.2023.107585_bb0735","doi-asserted-by":"crossref","first-page":"531","DOI":"10.3174\/ajnr.A5069","article-title":"Basilar artery changes in Fabry disease","volume":"38","author":"Manara","year":"2017","journal-title":"AJNR Am. J. Neuroradiol."},{"issue":"4","key":"10.1016\/j.ymgme.2023.107585_bb0740","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1161\/STROKEAHA.118.024426","article-title":"Effect of enzyme replacement therapy on basilar artery diameter in male patients with Fabry disease","volume":"50","author":"Miwa","year":"2019","journal-title":"Stroke."},{"issue":"5","key":"10.1016\/j.ymgme.2023.107585_bb0745","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1093\/cvr\/cvaa272","article-title":"Development, validation, and implementation of biomarker testing in cardiovascular medicine state-of-the-art: proceedings of the European Society of Cardiology-Cardiovascular Round Table","volume":"117","author":"Elliott","year":"2021","journal-title":"Cardiovasc. Res."},{"issue":"5","key":"10.1016\/j.ymgme.2023.107585_bb0750","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.3390\/jcm9051325","article-title":"A proteomics-based analysis reveals predictive biological patterns in Fabry disease","volume":"9","author":"Tebani","year":"2020","journal-title":"J. Clin. Med."},{"issue":"8","key":"10.1016\/j.ymgme.2023.107585_bb0755","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s11886-020-01317-x","article-title":"Artificial intelligence-enabled ECG: a modern lens on an old technology","volume":"22","author":"Kashou","year":"2020","journal-title":"Curr. Cardiol. Rep."},{"issue":"13","key":"10.1016\/j.ymgme.2023.107585_bb0760","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.2174\/0929867324666170616102112","article-title":"Biomarkers for diagnosing and staging of Fabry disease","volume":"25","author":"Kramer","year":"2018","journal-title":"Curr. Med. Chem."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719223002159?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719223002159?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T23:54:08Z","timestamp":1761090848000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719223002159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":152,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S1096719223002159"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2023.107585","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An expert consensus on the recommendations for the use of biomarkers in Fabry disease","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2023.107585","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"107585"}}